RecruitingNot applicableNCT05566769
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
Studying Neuromyelitis Optica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ad scientiam
- Intervention
- NMOSDCopilot smartphone application(device)
- Enrollment
- 103 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (22)
- University of Southern California, Los Angeles, California, United States
- University of California Davis Health, Sacramento, California, United States
- University of south Florida, Tampa, Florida, United States
- NorthShore University HealthSystem, Evanston, Illinois, United States
- Johns Hopkins Outpatient Center (now called Levi Watkins, Jr., M.D., Outpatient Center), Baltimore, Maryland, United States
- Massachussets General Hospital, Boston, Massachusetts, United States
- Washington University in St. Louis, Washington, Missouri, United States
- CC Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
- Hôpital Roger Salengro, Lille, France
- CHU Marseille - La Timone, Marseille, France
- CHU de Montpellier, Montpellier, France
- Hopital Pasteur 2, Nice, France
- Hopital La Pitié Salpétrière, Paris, France
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05566769 on ClinicalTrials.govOther trials for Neuromyelitis Optica
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT05909761Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During PregnancyAmgen
- RECRUITINGPHASE3NCT05199688A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)Hoffmann-La Roche
- RECRUITINGPHASE4NCT07420296Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderTianjin Medical University General Hospital
- RECRUITINGNCT06885957Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSDTongji Hospital
- RECRUITINGPHASE1NCT06620809The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum DisordersTongji Hospital
- RECRUITINGNANCT06865274Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT06780709Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSDIcahn School of Medicine at Mount Sinai
- ACTIVE NOT RECRUITINGPHASE3NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDAlexion Pharmaceuticals, Inc.